Elotuzumab, pomalidomide, and dexamethasone is a very well tolerated regimen associated with durable remission even in very advanced myeloma: a retrospective study from two academic centers

BACKGROUND: The anti-SLAMF7 monoclonal antibody, elotuzumab (elo), plus lenalidomide (len) and dexamethasone (dex) is approved for relapsed/refractory MM in the U.S. and Europe. Recently, a small phase 2 study demonstrated an advantage in progression-free survival (PFS) for elo plus pomalidomide (po...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:J Cancer Res Clin Oncol
Hauptverfasser: Hose, Dorothea, Schreder, Martin, Hefner, Jochen, Bittrich, Max, Danhof, Sophia, Strifler, Susanne, Krauth, Maria-Theresa, Schoder, Renate, Gisslinger, Bettina, Einsele, Hermann, Gisslinger, Heinz, Knop, Stefan
Format: Artigo
Sprache:Inglês
Veröffentlicht: Springer Berlin Heidelberg 2020
Schlagworte:
Original Article – Clinical Oncology
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7810646/
https://ncbi.nlm.nih.gov/pubmed/32683487
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00432-020-03323-6
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge